BMC Cancer

Table 1 Summary of the clinicopathological parameters of gastric cancer according to the expression of SOX2 and CDX2

From: Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome

	SOX2					CDX2
	Negative		Positive			Negative		Positive
	N	%	N	%	p	N	%	N	%	p
Age, years¹
Mean ± SD	65.8 ± 12.7		63.4 ± 13.5		0.2	64.1 ± 13.6		65.2 ± 12.6		0.6
Median (Range)	69 (34-85)		66.5 (24-89)			69 (24-89)		67 (36-89)
Sex¹
Male	52	41.9	72	58.1	0.02	75	60.5	49	39.5	0.1
Female	45	58.4	32	41.6	0.02	38	49.4	39	50.6	0.1
TNM stage²
I/II	35	54.7	29	45.3	0.09	26	40.6	38	59.4	0.002
III/IV	59	44.7	73	55.3	0.09	83	62.9	49	37.1	0.002
T stage³
T1/T2	22	62.9	13	37.1	0.03	13	37.1	22	62.9	0.007
T3/T4	75	45.5	90	54.5	0.03	99	60.0	66	40.0	0.007
N stage¹
N0	28	62.2	17	37.8	0.03	20	44.4	25	55.6	0.07
N+	69	44.2	87	55.8	0.03	93	59.6	63	40.4	0.07
Margins⁴
R0	85	47.5	94	52.5	0.5	98	54.7	81	45.3	0.2
R1	11	55.0	9	45.0	0.5	14	70.0	6	30.0	0.2
Vascular invasion⁴
Negative	39	55.7	31	44.3	0.1	37	52.9	33	47.1	0.5
Positive	57	44.2	72	55.8	0.1	75	58.1	54	41.9	0.5
Láuren⁵
Intestinal	44	49.4	45	50.6	0.9	45	50.6	44	49.4	0.3
Diffuse	20	48.8	21	51.2		26	63.4	15	36.6
Unclassified	31	46.3	36	53.7		40	59.7	27	40.3
Ming⁶
Expansive	32	53.3	28	46.7	0.5	28	46.7	32	53.3	0.1
Infiltrative	60	45.8	71	54.2		81	61.8	50	38.2
Unclassified	2	66.7	1	33.3		1	33.3	2	66.7
SOX2¹
Negative						58	59.8	39	40.2	0.3
Positive						55	52.9	49	47.1	0.3
CDX2¹
Negative	58	51.3	55	48.7	0.3
Positive	39	44.3	49	55.7	0.3
MUC5AC¹
Negative	39	44.8	48	55.2	0.4	42	48.3	45	51.7	0.05
Positive	58	51.3	55	48.7	0.4	70	61.9	43	38.1	0.05
MUC2¹
Negative	69	48.6	73	51.4	0.9	84	52.2	58	40.8	0.1
Positive	27	48.2	29	51.8		26	46.4	30	53.6

¹N = 201; ²N = 196; ³N = 200; ⁴N = 199; ⁵N = 197; ⁶N = 194.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com